Please assess the completion status of the following clinical trial:

Trial Title: LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women at least 18 years of age with a diagnosis of definite or probable AIH defined by the revised International Autoimmune Hepatitis Group (IAIHG) criteria~* Elevation of serum ALT ≥ 1.5 times the upper limit of normal~* Liver biopsy showing chronic hepatitis consistent with AIH~* Patients able to swallow the study medication~* Patients capable of understanding the purposes and risks of the study, who can give written informed consent and who are willing to participate in and comply with the study~* Women of childbearing potential must have a negative serum pregnancy test within seven days prior to receiving study medication and agree to use contraceptive measures to avoid pregnancy during participation in the trial.~Exclusion Criteria:~* Patients with other concurrent liver disease~* Patients with cirrhosis on liver biopsy with a MELD score \> 15~* Patients with a history or presence of decompensated liver disease~* Patients with serum creatinine ≥ 1.5 mg/dL prior to enrollment~* Patients positive for HCV RNA or Hepatitis B surface antigen (HBsAg)~* Patients with a history of alcohol intake \> 25 g/day within the past six months~* Patients with TSH outside normal range accompanied by an abnormal T4~* Patients with alpha-fetoprotein ≥ 20 ng/mL~* Patients with severe anemia (hemoglobin \< 8 g/dL), leukopenia (WBC \< 4000/mm3), or thrombocytopenia (platelet count \< 100,000/mm3)~* Patients with a history of recent exposure to hepatotoxic drugs~* Patients who require therapy with any immunosuppressive agent other than those prescribed in the study~* Patients unable or unwilling to provide informed consent~* Pregnant or nursing women~* Patients with reproductive potential who are unwilling/unable to use a double barrier method of contraception~* Patients who have been treated with another investigational agent in the three months prior to enrollment~* Patients receiving any drug interfering with tacrolimus metabolism~* Patients with current malignancy or a history of malignancy (within the past 5 years), except basal or non-metastatic squamous cell carcinoma of the skin that has been treated successfully~* Patients with uncontrolled concomitant infection, a systemic infection requiring treatment, or any other unstable medical condition that could interfere with the study objectives~* Patients with severe diarrhea, vomiting, active peptic ulcer or gastrointestinal disorder that may affect the absorption of tacrolimus~* Patients with a known hypersensitivity to azathioprine, corticosteroids or tacrolimus~* Patients with any form of current substance abuse, psychiatric disorder or a condition that, in the opinion of the Investigator, may invalidate communication with the Investigator~* Patients who are recipients of an organ transplant or who require treatment with immunosuppressives or corticosteroids for any disease other than AIH.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LCP-Tacro (Type: EXPERIMENTAL): LCP-Tacro tablets(1,2,and 5mg tacrolimus)+ prednisone tablets(5mg)
- Azathioprine (Type: ACTIVE_COMPARATOR): Azathioprine tablets(50mg)+ prednisone tablets(5mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).